Presentations from sin delantal, onco vision, indisys, minima espresso systems, yunait, tusjuegos.com @Spain_Startup & Investor Summit (follow us on Twitter)

1. Startup Pitches
Modera: Paris de l’Etraz

2. Varis, Natalia
SIN DELANTAL

3. SinDelantal, order food online from delivery & takeaway
restaurants

8. Evolution of
orders
Number of
restaurants

9. Next
steps

10. Thanks
!
SinDelantal.com, june 2011

12. Gabriel Barón
ONCOVISION

13. Vision Technology to Cure Cancer
Gabriel Gonzalez Pavón, MD
Spain Startup & Investor Summit
Madrid, 7th of June, 2012
13

14. My (very) personal journey: “Don Quijote rides again”
• From surgery to an outstanding Corporation during 21 years
• … and from seven business units, two secretaries, Global and European Corporate Boards and a
“corner office” to a corner garage
• Creating a highly profitable business by making a real difference in curing cancer, patient by
patient, with breakthrough innovation
…and my story is one of many similar at Oncovision

15. 1a. Cancer: the enemy inside
“FIRST CAUSE OF DEATH WORLDWIDE SINCE 2010”
(World Health Observatory UN/WHO, December, 2009) Incidence, colon cancer, 2010
• Cancer is a generic term encompassing 200+ types of malignant tumours, with very significant
mortality and growing incidence
– 165.000 new cases diagnosed per year in Spain, 80+ million of new patients per year worldwide
– Case in point: Mortality by breast cancer: 480.000+ worldwide, best case survival 77%, often under 50%
“Abnormal growth of tissues or cells which expands both locally and at a distance, in other parts
of the body, invading first regional lymph nodes (in more than 90% of tumours) and generating
later metastasis (new satellite tumours in other locations)”
Two hundred+ enemies, no unique or “magic” solution
PERSONALIZED CARE CRITICAL

16. 1b. Cancer: Still many unsolved questions, lives at risk
“25% to 30% of node
negative breast cancer ¿Why do I have high (>27% ) recurrence rates
after “oncologically correct” surgery in advanced
patients will develop local colon cancer?. How can my patients do better?
recurrences or distant S. Saha (McLaren Regional Medical Center, Flint, MI, USA at the VII World
metastases within 10 years. Congress of the ISNS (International Sentinel Node Society, November
2011)
Studies have suggested that this
unfavorable outcome may be due in
part to undetected occult
metastases in the lymph
nodes”
A. Sahin,M. Guray, Kelly K.
“Functional drainage –as seen in
Hunt, MD Anderson. Arch Patol lymphogammagraphy- is different from the
Lab 2009 classic anatomical drainage patterns used as
reference for surgery in 10 to 30% of melanoma
patients, depending on lesion localization”
Uren R et al. J NuclMed2003; 44:570-582
16

17. 2. Molecular Vision : “New Eyes” to fight cancer
• There are two (complementary) ways of seeing inside people:
• Structural imaging explorations (RX, CT, MRI) are detecting with great accuracy anatomical changes vs
“normal” body structures
• Functional (molecular) imaging (gammagraphy, PET, SPECT) is detecting and quantifying abnormal
functional activity, often BEFORE having anatomical visible impact, and measuring its evolution
• The new ORIGINAL technology of Oncovision is making possible “seeing cancer” in real
time, know it better, patient by patient, and act against it.
Mammography PET
Breast cancer, 35
years old female
17

18. 3. The great business of “doing what is right”
• Breakthrough Innovations 2006-2012
– From one prototype to THREE huge potential highly differentiated product lines
– VERY strong support from leading global reference centers… and sales in 28 countries
– Multiaward winning (i.e. Best Technology Company of Spain, 2012, best preclinical innovation strategy, USA, 2011, “Jaime I”
Entrepeneurship Award 5th of June 2012 …)
– Powerful pipeline and additional new lines sharing core technology & strategic alliances
• From dreams to Discipline
– High profile and experienced international team… also at finance, purchasing, manufacturing, market
development, sales, regulatory affairs…
– VERY rigurous management of timelines, budgets, commitments, quality
– REAL synergy at work: R&D alliance I3M, venture capital BULLNET, AXIS-ICO, partners & allies
• Daring and Doing
– Aiming to the top KOL and cancer centers, benchmarks, ONLY perfect is good enough
– Proactiveness, proactiveness, proactiveness… AND customer focus / SERVICE network
ONCOVISION GAINS NET POSITIVE RESULTS IN 2012

19. 4. Innovation brings global profitable growth
• Equipment for cancer care: an unique opportunity
– Unlimited, global demand vs resistance to change, budgets and marketing power
– New technology does not penetrate clinical practice easily: needs to prove clinical AND economic
advantages, regulations and reimbursement, leader and USER training
– Medical equipment is not (only) software: manufacturing, logistics, homologation, local service
• From start up to global enterprise, step by step… and fast
– Upgrading team and capabilities
Sales growth
– Managing development
– Financing production
– Fueling indication expansion
– Expanding global network
– Building alliances

20. 5. How?: A crystal clear business model for explosive expansion
• Three step “Magic Johnson approach”. Shared PRACTICAL deployment & excecution, by
product and geography, of OCV´s core strategy, creating new / uograding markets and bringing
profitable growth
• EVIDENCE by pathology, country / region
Strong clinical
• REFERENCES with top centers for support and training
• ALLIES in financing, distribution/marketing, technical
service, development, externalization of production, scientific societies, patient
advocacy groups, media, insurance companies…
• Programmed launching of INNOVATIONS
• FLEXIBLE and proactive competitive positioning
• Managing aggressive SUSTAINABLE global growth
20

21. 6. THREE revolutionary product lines in global expansion (1/3)
• The base of it all, and a worldwide success, redefining personalized cancer surgery
• EXCLUSIVE FULLY INTEGRATED cancer detection EQUIPMENT gammacamera + pointers + gamma probe + CAD
software for REAL TIME VISION in the OR of tumors and lymph nodes.
 Revolution en RADIO_GUIDED SURGERY (beginning with Sentinel node biopsy) of both superficial and
deep draining tumors.
 GUARANTEES and documents completness of cancer surgery, patient by patient
 SEVEN additional high volume indications: critical care, encephallic death
confirmation, trasplant, treatment control in advanced chemoteraphy, cardiac reconstruction, diabetic
foot, “ligth” gammagraphy in remote Hospitals
 105+ units installed in 28 countries, 20.000+ patients, 26 cancer types (June 2012)
 VERY STRONG clinical and economic evidence and support from top global oncology centers
 Market undergoing explosive growth (VISION + expansion from 12 a 150+ tumours…)
21

22. DEVELOPMENT TIME TO
OPTIMIZED
PRODUCT: 4 YEARS
First clinical prototype camera ,
October 2004
NEW Sentinella 2
Third generation Sentinella 102,
April, 2011
September 2008
22
INTEGRATED gamma camera + gamma probe + pointer + CAD software

23. Sentinella in acction: Prostate cancer surgery at NKI-AWL Amsterdam
Courtesy of Drs. R. Valdés, A Bex, S. Horemblas
23
NKI-AWL, Amsterdam, The Netherlands

24. 6. THREE revolutionary product lines in global expansion (2/3)
• The most complex product line, multimodal equipment for advanced in-vivo research
in rats and mice in oncology, neurology, cardiology and new drug / treatment development
• EXCLUSIVE FULLY INTEGRATED PET+SPECT+CT with unqualled performance AND ease of use
 Changing basis of competition in preclinical imaging (lower costs, faster explorations, easy
maintenance and MODULAR upgrade options)
 OCV markets direct in Spain and Portugal, ROW CARESTREAM MOLECULAR IMAGING
 19 units installed in 14 countries -15+ underway in 2012-, 30.000+ studies (June 2012)
 VERY competitive vs previous best in class SIEMENS, only two other (minor) competitors
 Market undergoing major growth (core labs, pharma companies, upgrade to multimodal…)
24

25. ALBIRA MULTIMODAL (PET+SPECT+CT), September 2008
Prototype IFIC, December 2005
Albira PET, November 2007
DEVELOPMENT TIME TO
OPTIMIZED PRODUCT: 2 1/2
25
YEARS

26. Same soul, upgraded capabilities, new face, global success:
Albira II, March 2010
Best Preclinical Innovation
strategy award 2011, USA
26

27. Skeleton & abdominal organs, mouse
FOUR simultaneous mice studies!
Mouse heart
FIVE vision modalities Albira + Carestream
Fusion PET (3D) & 3D MRI. Brain ischemia, mouse
27

28. 6. THREE revolutionary product lines in global expansion (3/3)
• A clinical evolution of Albira PET, the biggest potential of all (medium term 4.400 centers, long 40.000+) and a true
breakthrough im breast cancer diagnosis and treatment assessment
• GLOBAL EXCLUSIVE TRUE 3D, prone position NO compression dedicated PET mammography, with unprecedented
diagnostic reliability, very fast explorations, minimal radiation dose (below X ray mammography, of which it is complementary)
and remarkable ease of use
• Detects and measures agressiveness of possible BC tumors even of minimal size, in young women, dense or fibroquistic
breasts, differentiating benign from malign lesions
 Indicated in very early diagniosis of breast cancer in women from groups of risk, confirmation of suspicious
lesions identified in screening, avoiding unnecessary biopsies, local follow up post surgery and VERY fast (<3
weeks vs 10-12) and effective measurement of results of chemotherapy, hormonoteraphy or radiotheraphy
 Launched November 2011, 4 units installed (6 underway short term) in 4 countries
 VERY STRONG clinical support from top global oncology centers
28

29. Whole body PET
Mammi dedicated PET
Vastly improved accuracy
and quantification
First MAMMI installed at NKI Amsterdam, May 2011

30. EXCLUSIVE TRUE 3 D

31. 9. The best is yet to come: Developments under way
1. (Funded) Innovations & clinical improvements in EXISTING product lines
• Further capabilities and ease of use: expansion modules and upgrades
(multimodality, 3D, improved resolution, sensitivity, speed, software, ergonomics…).
• Product segmentation by clinical indication:
(Dedicated equipment configurations i.e cardiac, critical care, portable gamma units, software variants…)
• Improved auxiliary elements to further optimize tumour detection AND treatment
2. (Funded) Major technology upgrades and cost reductions
• Detectors, electronics, software, engineering i.e targeting 40% cost reduction in 2 years
• Vast performance improvement based in exclusive continuous crystal – based modules
3. (Funded) NEW product lines, sharing core technology and expertise
• Neuro-PET for cerebrovascular (i.e. stroke), cancer and neurodegenerative diseases
• PET-MRI & other clinical and other multimodality options
• “Metastases search “units, including CAD and other surgical decision support tools
• Surgical / interventional navigation equipment
31

32. 10. In conclussion, how does Oncovision measure up?
– THREE active, breakthrough product lines based on shared core technology
• PROVEN INNOVATIVE, ORIGINAL, PATENTED TECHNOLOGY
• Very significant and expanding market opportunities and new lines (i.e Neurology)
• Very close alliances with key innovators
– PRESENCE WITH SENTINELLA IN 28 COUNTRIES, ALBIRA in 15, MAMMI in 4
• Outstanding published evidence and global leader personal support
• Strong evidence and reference center network
• CARESTREAM ALLIANCE and other strategic negotiations underway
– PROVEN MANUFACTURING, COMMERCIAL and REGULATORY CAPABILITIES
– OUTSTANDING DIRECT and allied INNOVATION and DEVELOPMENT teams
– A TRUSTWORTHY PARTNER FOR TODAY AND TOMORROW
– A SOUND, HIGHLY PROFITABLE INVESTMENT
32

33. Vision Technology to Cure Cancer
New facility at CIPF Valencia, Spain 33

35. Pilar Manchón
INDISYS

36. BUSINESS PLAN: INTERNATIONALIZATION
INTELLIGENT NATURAL LANGUAGE SOLUTIONS
PILAR MANCHÓN

37. Challenge
• Large organizations seek:
– Increasing revenue
– Minimizing costs
– 24x7 customized & excellent support
– Excellent UX
– Information exploitation & management

38. Global Solution
“One coherent, excellent & personalized User Experience across all channels”.
Mobile Virtual Assistants
Social Media
Online Virtual Email
Assistants Response
Management
Virtual E-Learning
Telephone
Operators Live Chat

39. Human Capital
Executive Team Board of Advisors
Pilar Manchón: PhD Kenneth Morse
Gabriel Amores: PhD Laura Morse
Guillermo Pérez: PhD Juan Martínez Barea
Investors
• Founders: €80K
• Business Angels €193K
• VC (Invercaria) €527K

40. Indisys: The company
Awards Team Background
• Call To Innovation 2012
• Computational Linguistics
• “Cool Vendors 2010”
• Innovation Award 2010
• Artificial Intelligence
• Innovation Award 2009 • Cognitive Science
• Best User Experience 2009
• Machine Learning
• Computer Science
• Telecommunications
Headcount
20

41. Technology: locuaz
Domain & language independent brain that engages the
user in intelligent and flexible human-like dialogue.
Maya

42. International Success Stories

43. Market Size & Competition
• $ 1 B for Virtual Assistants (Gartner 2012)
+$ 3.5 B
• $ 1,5 B for Virtual Operators (Frost & Sullivan 2011)
• $ 1 B? for SME VA untapped market (Indisys 2012)
• $ xx B? for B2C Mobile Applications
• Small number of competitors
• None with equal or superior technology
Competitive Advantage
• Experienced & committed team
• Superior Technology
• Great references
• Strategic Partners
• Position, visibility, brand image

44. What we seek… What it is for…
B-round: • Finance existing opportunities
• Creating more opportunities
• Increasing Sales & Exec Team (US)
• Patenting the technology
$ 2-3 M • Financing additional revenue channel
• Growing fast to lead the market
Our Objective
“Total global domination of our market niche”
Kenneth P. Morse

45. We look forward
to working with
you.
Thank you!
Pilar Manchón
Intelligent Dialogue Systems
p.manchon@indisys.es
+34 625 377 440
+1 650 804 0867

47. Xavier Samsó
MINIMA

49. The Autonomous Coffee Maker
New concept of outdoors:
Espresso anywhere-anytime
Portable, autonomous, free of
energy sources.
The System: Fluid compression
IP Protection
Freedom to Operate
Applications for coffee makers
and other sectors

50. Professional Coffee makers
… 1950 1961 1990 2012
…
The New Generation
Flat Professional coffee makers
Direct exploitation to coffee
roasters
Home Coffee Makers
Technology transfer
Strategic alliances

51. Competitive advantages
Perfect Coffee Compatibility
For all
Top Espresso Espresso
Quality Systems
Low Production Energy Savings
Costs
Simplicity of 80 % less
components electricity
No Calcification Silent
Technic Service No noises while
friendly operating

52. Our Company
8 experienced owners
Average of 46 years old
5 Employees at I+D
5 Tech Centers:
ASCAMM, CIM, CRIC, IRTA,LEITAT
Investments
Share Capital: 215.000 € New Investments 2012-13
Private Investors: 250.000 € Shares & Private: 500.000 €
CDTI: 295.000 € ENISA: 150.000 €
ENISA: 100.000 € Cdti: 250.000 €
Total investments: 860.000 € Total 2012/13: 900.000 €

53. Road Map to success
Research, technology feasibility,
2009 – April 2012 IP protection
Product range
Stategic Alliances
End of 2012
Technology transfer agreements
Capital Increases
April 2013 Launch
Autonomous Coffee Makers
May 2012 – June 2013 Professional Coffee Markers Project
Launch
October 2013 Professional Coffee Makers

54. To innovate we need to imagine

57. Pablo Elosúa
YUNAIT

58. pablo elosúa
founder & ceo
one stop place
for daily deals

59. all deals in
one
web / email
free your inbox!

60. user power
we let the user decide

61. we know what
our users
love
user intelligence

62. dealhunter
deals on the
go

63. 500K
users

64. business model
qualified traffic
partner
sites
revenue

65. market
€5bn
global

66. market
€200m
year (spain)

67. our performance
€1m
monthly sales
through yunait

68. our performance
1,500
coupons sold
everyday

69. spain
uk
italy
brazil
portugal

70. dream team

71. thanks!

73. Thomas Petit
TUS JUEGOS

75. What we do
Digital videogames Ecommerce
localized for Latin markets
Digital downloads
Games for PC & Mac
Full localization
1000+ titles
All discounted from retail price

76. Founders & Staff
Inversores
Jaume Ferre Carlos Blanco Sergio Rincón Ramon Farell
CEO Business Dev. Key Partnerships Sales Strategy
Team
10 pax
Eloi Poch Thomas Petit Rúben Jimenez
IT & Operations Marketing Product Manager

77. Our Market
Volume
# Players Games $ PC/Mac % Digitalized
SP 16M 1,6 MM€ 480 M€ <40%
BR 35M $2 MM $600 M 50%
IT 14M 1,7 MM€ 510M € <40%
Source
FR 24M 3,2 MM€ 800M € 45%
US 145M 21,6 MM€ 4300M € >60%
Trend: Digitalization

78. Current Status
Funding Operations/Sales
200,000+€ from founders 2011 Shop opens
400,000+€ Seed Capital 2012 Traction > growth
News
http://TusJuegos.com/Solidario/